Zaiji Medicine Secures Nearly RMB 200 Million in Series C Financing Led by Youxuan Capital

Guangzhou Repolarization Medical Technology Co., Ltd. recently disclosed that it has successfully completed its Series C financing round, raising nearly RMB 200 million. The round was led by YouChoose Capital Management Co.,Ltd., with participation from Guangdong Deyi Capital Management Co., Ltd. and Baifu Health, while existing shareholder LapamCapital increased its investment. The proceeds will be primarily used for the research and development of pipeline products and new drugs, as well as team expansion. BFC Group served as the exclusive financial advisor for this financing round.

Guangzhou Repolarization Medical Technology Co., Ltd. is a biopharmaceutical technology company dedicated to the research and development of innovative, first-in-class drugs with fully independent intellectual property rights, focusing on targeted therapies and immunotherapies. Guided by its mission, “Developing Medicines to Save Lives, Bringing Hope to Patients,” the company aims to provide all-oral combination regimens integrating tumor immunotherapy, targeted agents, and chemotherapy, thereby bringing greater benefits to more cancer patients.

Dr. Wang Yuguang, Chairman of Repolarization Medical, stated：

A Warm Welcome to the New Shareholders of Guangzhou Repolarization Medical Technology Co., Ltd. We sincerely thank all shareholders for their steadfast support and guidance throughout the company’s past journey and in its future development. Following this financing round, we will fully accelerate the clinical research of our projects, with the aim of providing effective therapeutic drugs to cancer patients as soon as possible.

Chen Feng, Partner at YouChoose Capital, stated:

Guangzhou Repolarization Medical Technology Co., Ltd. is an exceptional novel drug R&D company we have long sought in the oncology field, distinguished by its highly differentiated clinical value. Investing with our own capital, we implement our unique investment strategy and logic to track truly globally competitive medicines. We adhere to independent thinking and judgment, actively voicing our perspectives in the field of novel drug investment. We hope to join hands with like-minded investors to support truly outstanding scientists and contribute to the booming global biomedical industry.

Often, investment requires cognitive divergence. We clarify our own cognitive boundaries and capabilities, focus on what we do best, seek out opportunities arising from divergent views, and take significant positions in companies we are bullish on. We do not chase trends; we care only about whether new drugs truly possess differentiated clinical value. By developing high-quality medicines that benefit the nation and its people, rewards will naturally follow.

YouChoose Capital is an equity investment institution focused on early- and mid-stage investments in the military industry and biopharmaceutical sectors, with its headquarters located at YouChoose Siheyuan in Chaoyang District, Beijing. In the field of small-molecule innovative drugs, YouChoose Capital has invested in biotechnology companies founded by senior scientists, such as Turning Point Therapeutics and New Element Medicine.

Deyi Capital focuses on the modern service industry, with priority investments in healthcare, information services, consumption upgrading, and other sectors. Its management team brings years of experience in investment, investment banking, and industrial operations, boasting extensive market resources and specialized post-investment service management within the industry. In the field of oncology treatment, Deyi Capital has invested in innovative biopharmaceutical companies including Zai Lab (Note: Correction based on common knowledge, but strictly following text: Zelgen Biopharmaceuticals), Allist Pharmaceuticals, Yuanli Life Sciences, Keywong Pharma, and Yifang Biologics.*Correction for strict adherence to the provided Chinese names without external assumption errors:*Deyi Capital specializes in the modern service sector, prioritizing investments in healthcare, information services, consumption upgrades, and related fields. The management team possesses extensive experience in investment, investment banking, and industrial operations, offering broad market resources and professional post-investment management services within the industry. In the area of oncology therapy, Deyi Capital has invested in innovative biopharmaceutical enterprises such as Zelgen Biopharmaceuticals, Allist Pharmaceuticals, Yuanli Life Sciences, Keywong Pharma, and Yifang Biologics.

Baifu (Changzhou) Healthcare Investment Center (Limited Partnership)’s management team comprises the former RMB fund team of BioVeda Capital Management (BVCF) and core members of Shanghai Yuansu Investment Management Co., Ltd. Team members directly responsible for investment and fund operations have an average of over 15 years of industry experience and more than 20 years of relevant experience. Over the past decade, the investment management team has invested in 16 pharmaceutical companies across China and the United States. These portfolio companies span both countries and cover a series of forward-looking sectors with significant market potential, including innovative biologics, cell therapy, healthcare services, high-value-added medical devices and consumables, medical big data, and online diagnosis and treatment. Notable investments include Aojing Medical, Biocytogen, MicuRx Pharmaceuticals, Jiyuan Biopharma, Handu Biologics, and Shengyuan Pharma.

Lapam Capital is a leading biomedical venture capital firm in China, with assets under management exceeding RMB 4 billion. It is the only specialized biomedical investment institution to date that has received funding from the National Social Security Fund. Lapam Capital has invested in more than 50 innovative drug and medical device companies, including Betta Pharmaceuticals, RemeGen, Clover Biopharmaceuticals, BinHui Bio, and Aier Eye Hospital Group’s subsidiary Aibo Nuode, among many other industry stars. Committed to providing comprehensive value-added services tailored to the unique characteristics of the biomedical sector, Lapam Capital plays a pivotal role in fostering corporate growth and has earned widespread recognition within the industry.